Combining targeted therapy drugs may treat previously resistant tumors

December 01, 2008

Blocking 2 cell signalling pathways leads to dramatic shrinkage of K-Ras-mutated tumors in animal model

A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches. In their Nature Medicine report, which is receiving early online release, investigators from Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH) Cancer Center, and Beth Israel Deaconess Medical Center (BIDMC) Cancer Center report that combining two different kinase inhibitors - drugs that interfere with specific cell-growth pathways - led to significant tumor shrinkage in mice with lung cancer driven by mutations in the K-Ras gene. In addition to their association with nearly 30 percent of cases of non-small-cell lung cancer - the leading cause of cancer deaths in the U.S. - K-Ras mutations are involved in many cases of colon cancer and most pancreatic cancers, which are extremely resistant to treatment.

"Finding a way to effectively treat K-Ras-mutated cancers would be a huge advance in solid tumor oncology, since these mutations are common in several incurable cancers," says Jeffrey Engelman, MD, PhD, of the MGH Cancer Center, one of the report's co-lead authors. "Cancers with K-Ras mutations have been resistant to all targeted therapies to date, and it is exciting to learn that a combination of PI3K and MEK inhibitors, two families of drugs currently in clinical development, may be highly effective in these cancers."

The current study began with a focus on the PI3K signaling pathway, which is key to cell survival and known to control cellular motility and adhesion. PI3K mutations have caused tumor development in laboratory studies, but their role had not yet been studied in an animal model. The research team developed a transgenic mouse in which administration of the drug doxycycline induces the expression of cancer-associated PI3K mutations, leading to development of lung tumors.

Treatment of those animals with an investigational PI3K inhibitor did lead to rapid tumor regression. Since previous studies suggested that PI3K inhibition might also block K-Ras-induced tumor development, the investigators also tested the PI3K inhibitor in mice with K-Ras-stimulated tumors. That treatment was ineffective, but since K-Ras also activates the MEK/ERK signalling pathway, the researchers treated the animals with an investigational MEK inhibitor and with a combination of both drugs. Treatment with the MEK inhibitor alone caused only a modest reduction in tumor size, but combined treatment with both agents caused the K-Ras-stimulated lung tumors to virtually disappear.

"For several years we have known that K-Ras activates two major pathways - the PI3K pathway and the MEK/MAPK pathway - and that these pathways have many redundant functions in tumor growth and survival," says Lewis Cantley, PhD, of the BIDMC Cancer Center, one of the study's co-corresponding authors. "Inhibitors of both of these pathways are now in clinical trials, and in this paper we show that, while either agent alone has a minor effect on K-Ras-driven tumors in mice, combining inhibitors of both pathways eradicates these tumors with minimal toxicity."

Kwok-Kin Wong, MD, PhD, of DFCI, also a co-corresponding author, adds, "The results of our study are truly remarkable and provide a strong and compelling scientific rationale to test this combination therapy in human phase 1 and 2 trials. This work would not have been possible without the highly productive collaboration between our laboratories at Mass. General, Beth Israel-Deaconess and Dana-Farber." Wong is an assistant professor of Medicine at Harvard Medical School, where Engelman is also an assistant professor in Medicine, and Cantley is the Castle Professor of Medicine.

The researchers are hoping to advance towards clinical trials by testing combination therapy against other models of K-Ras-mutated cancer, including those that involve additional mutations in other tumor-associated genes, and to investigate whether K-Ras-associated tumors will become resistant to combination therapy, a problem that has plagued other targeted cancer therapies.

Massachusetts General Hospital

Targeted Cancer Therapy (Current Clinical Oncology)
by Razelle Kurzrock (Editor), Maurie Markman (Editor)

Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology, this volume provides a state-of-the-art overview. It will be valuable to practicing and academic physicians, fellows, residents and students, as well as basic scientists, interested in the cancer field.

Randomized Trial to Evaluate Efficacy and Safety of Combination Budesonide and Formoterol and New FDA Mandate Regarding LABAs (Hospital Practice)
by JTE Multimedia

Original Article Noonan M, Rosenwasser LJ, Martin P, O’Brien CD, O’Dowd L. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;6(17):2235–2254. PRACTICE PEARL Data from this randomized trial demonstrates that combination therapy with ICSs and LABAs increases FEV1 and improves asthma control and symptomatology compared with monotherapy alone in patients with moderate-to-severe asthma; recent FDA recommendations regarding use of LABAs must also be considered.

Antiepileptic Drugs: Combination Therapy and Interactions
by Jerzy Majkowski (Editor), Blaise F. D. Bourgeois (Editor), Philip N. Patsalos (Editor), Richard H. Mattson (Editor)

This book reviews the use of antiepileptic drugs focusing on the interactions between these drugs and between antiepileptics and other drugs. These interactions can be beneficial or can cause harm. The aim of this book is to increase awareness of the possible impact of combination pharmacotherapies. Pharmacokinetic and pharmacodynamic interactions are discussed supported by clinical and experimental data. The book consists of five sections covering the general concepts and advantages of combination therapies, the principles of drug interactions, the mechanisms of interactions, drug interactions in specific populations or in patients with co-morbid health conditions, and concludes with a look at the future directions for this field of research. The book will be of interest to all who...

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)
by Gary K. Schwartz (Editor)

Expert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy.

Combination Therapy for Asthma and Chronic Obstructive Pulmonary Disease (Lung Biology in Health and Disease)
by Richard Martin (Editor)

This book examines the therapies used for treatment of asthma and chronic obstructive pulmonary disease (COPD) separately and in combination, covering beta-agonists, theophylline, leukotriene modifiers, and anticholinergics. Highlights the importance of specific time dosing of medications! Revealing what medications to use and when to prescribe them, Combination Therapy for Asthma and Chronic Obstructive Pulmonary Disease · emphasizes anti-inflammatory therapy · compares and contrasts the side effects and efficacy of titration and various combinations · covers the steroid-sparing effect of combining inhaled corticosteroids and long-acting beta 2-agonists · includes over 1100 references that clarify outcomes among several different agents · details the mechanisms of inhaled...

Combination Therapy of AIDS (Milestones in Drug Therapy)
by Erik De Clercq (Editor), Anne-Mieke Vandamme (Editor)

An extensive assessment of combination therapy of AIDS. Main focus is put on the Highly Active Antiretroviral Therapy (HAART) but other therapies like salvage therapy are also discussed. The chapters cover efficacy, treatment, causes of treatment failure, clinical care, guidelines, pharmacology. The volume closes with an outlook on future perspectives.

Use of fixed-dose oral combinations: Advantages of early initiation of combination oral therapy include improved efficacy, fewer side effects, lower cost, ... better compliance. (Postgraduate Medicine)
by JTE Multimedia

Abstract: Early initiation of therapy to decelerate the decline in beta cell function and achieve low hemoglobin A 1c levels is advantageous in patients with type 2 diabetes. In this first of two articles on treatment of type 2 diabetes, the authors share their experience in optimizing therapy and advocate fixed-dose oral combinations because of lower cost, improved efficacy, better compliance, and fewer side effects. The second article (on page 15) looks at the use of injection therapy when oral therapy is not enough.

Original Publication Date: July 2006

Advances in Combination Therapy for Asthma and COPD
by Jan Lotvall (Editor)

Aimed at specialists in respiratory medicine, this new book comprehensively reviews the variety of agents currently available for treatment of asthma, COPD, and other airway diseases and covers practical guidelines as well as challenges and complications in their use. Advances in Combination Therapy for Asthma and COPD is the first book to address the complexity of multi-agent therapy and deal with management issues in an integrated fashion. A review of currently available agents and their applications, as well as new therapies soon to become available are outlined. Advantages of combined therapies and additional considerations that arise from multi-agent programs are highlighted.

Combination Therapies (No. 1)
by E. Garaci (Editor), Allan L. Goldstein (Editor)

Combination Therapy in Urological Malignancy (Clinical Practice in Urology)
by Philip H. Smith (Editor)

This book emphasizes the importance of combining the skills of surgeon, radiotherapist and medical oncologist in the management of patients with malignant tumors of the urinary tract. After introductory chapters on radiation therapy, chemotherapy and immunotherapy, the individual urological tumors are discussed. The volume examines the increasing role of surgical preservations and reconstruction and the role played by clinical trials. Other factors such as quality of life and cost of treatment are also dealt with. The assessment of therapeutic possibilities is unique; no other volume is devoted to combination therapy as such in urological malignancy.